BERKELEY, Calif.--(BUSINESS WIRE)--Jan. 12, 2006--XOMA Ltd. (Nasdaq:XOMA), a leading biopharmaceutical company in therapeutic antibodies, today announced four senior management appointments. Appointments include Robert (Bob) H. Gundel, Ph.D., vice president, scientific corporate development; Mary Haak-Frendscho, Ph.D., vice president, preclinical research and development; Mark White, vice president, cell and analytical development; and Paul Goodson, senior director, investor relations.
